ES2614878T3 - Métodos y composiciones para terapia farmacéutica oral - Google Patents
Métodos y composiciones para terapia farmacéutica oral Download PDFInfo
- Publication number
- ES2614878T3 ES2614878T3 ES11758551.3T ES11758551T ES2614878T3 ES 2614878 T3 ES2614878 T3 ES 2614878T3 ES 11758551 T ES11758551 T ES 11758551T ES 2614878 T3 ES2614878 T3 ES 2614878T3
- Authority
- ES
- Spain
- Prior art keywords
- subject
- agent
- neoplastic disease
- transfer agent
- methylol transfer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000000034 method Methods 0.000 title description 3
- 239000000203 mixture Substances 0.000 title description 2
- 238000002560 therapeutic procedure Methods 0.000 title 1
- 239000002775 capsule Substances 0.000 abstract description 8
- 239000003795 chemical substances by application Substances 0.000 abstract description 8
- AJKIRUJIDFJUKJ-UHFFFAOYSA-N taurolidine Chemical compound C1NS(=O)(=O)CCN1CN1CNS(=O)(=O)CC1 AJKIRUJIDFJUKJ-UHFFFAOYSA-N 0.000 abstract description 6
- 229960004267 taurolidine Drugs 0.000 abstract description 6
- 210000001198 duodenum Anatomy 0.000 abstract description 3
- 239000007903 gelatin capsule Substances 0.000 abstract description 2
- 201000010099 disease Diseases 0.000 abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 3
- 230000001613 neoplastic effect Effects 0.000 abstract 3
- 210000004369 blood Anatomy 0.000 abstract 2
- 239000008280 blood Substances 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 abstract 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 abstract 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 abstract 2
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 abstract 2
- 210000001630 jejunum Anatomy 0.000 abstract 2
- 210000002966 serum Anatomy 0.000 abstract 2
- RJGYJMFQWGPBGM-UHFFFAOYSA-N 1,2,4-thiadiazinane 1,1-dioxide Chemical compound O=S1(=O)CCNCN1 RJGYJMFQWGPBGM-UHFFFAOYSA-N 0.000 abstract 1
- MVQXBXLDXSQURK-UHFFFAOYSA-N 2-aminoethanesulfonamide Chemical compound NCCS(N)(=O)=O MVQXBXLDXSQURK-UHFFFAOYSA-N 0.000 abstract 1
- 239000008203 oral pharmaceutical composition Substances 0.000 abstract 1
- 210000002381 plasma Anatomy 0.000 abstract 1
- 230000036470 plasma concentration Effects 0.000 abstract 1
- 210000002784 stomach Anatomy 0.000 abstract 1
- 229950007343 taurultam Drugs 0.000 abstract 1
- 230000032258 transport Effects 0.000 abstract 1
- 239000002552 dosage form Substances 0.000 description 6
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 4
- 229920003134 Eudragit® polymer Polymers 0.000 description 4
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 4
- 238000000576 coating method Methods 0.000 description 4
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 4
- 239000011248 coating agent Substances 0.000 description 3
- 238000007654 immersion Methods 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical class OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 2
- 239000003246 corticosteroid Substances 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 229960000890 hydrocortisone Drugs 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 229960005205 prednisolone Drugs 0.000 description 2
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000003618 dip coating Methods 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/549—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame having two or more nitrogen atoms in the same ring, e.g. hydrochlorothiazide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
- A61K9/2846—Poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4816—Wall or shell material
- A61K9/4825—Proteins, e.g. gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/485—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4891—Coated capsules; Multilayered drug free capsule shells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Inorganic Chemistry (AREA)
- Communicable Diseases (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US35018310P | 2010-06-01 | 2010-06-01 | |
| US350183P | 2010-06-01 | ||
| US37031510P | 2010-08-03 | 2010-08-03 | |
| US370315P | 2010-08-03 | ||
| PCT/IB2011/001539 WO2011151722A2 (en) | 2010-06-01 | 2011-06-01 | Methods and compositions for oral pharmaceutical therapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2614878T3 true ES2614878T3 (es) | 2017-06-02 |
Family
ID=45067142
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES11758551.3T Active ES2614878T3 (es) | 2010-06-01 | 2011-06-01 | Métodos y composiciones para terapia farmacéutica oral |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US9028866B2 (enExample) |
| EP (1) | EP2575783B1 (enExample) |
| JP (2) | JP5926243B2 (enExample) |
| CN (1) | CN103118669B (enExample) |
| AU (1) | AU2011262308B2 (enExample) |
| BR (1) | BR112012030641B8 (enExample) |
| CA (1) | CA2801309C (enExample) |
| ES (1) | ES2614878T3 (enExample) |
| WO (1) | WO2011151722A2 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6207595B2 (ja) * | 2012-05-15 | 2017-10-04 | フィリップス ライティング ホールディング ビー ヴィ | 照明装置の制御 |
| US20190381058A1 (en) * | 2016-01-11 | 2019-12-19 | Cormedix Inc. | Methods and compositions for treating neuroblastoma in a juvenile mammalian body |
| US20190381060A1 (en) | 2016-01-11 | 2019-12-19 | Cormedix Inc. | Taurolidine treatment for myc-expressing tumors in mammalian bodies |
| CN119950728A (zh) * | 2016-01-11 | 2025-05-09 | 科医公司 | 用于治疗神经母细胞瘤及其他癌症的治疗性纳米颗粒 |
| US11541061B2 (en) | 2016-01-11 | 2023-01-03 | Cormedix Inc. | Neuroblastoma treatment with taurolidine hydrolysis products |
| HUE069333T2 (hu) | 2017-11-17 | 2025-02-28 | Evonik Operations Gmbh | Eljárás bevonatos kemény héjú kapszula elõállítására |
| EP3843746A4 (en) * | 2018-08-28 | 2022-10-19 | CorMedix Inc. | NEUROBLASTOMA TREATMENT WITH TAUROLIDINE HYDROLYSIS PRODUCTS |
| CA3111100A1 (en) * | 2018-08-31 | 2020-03-05 | Cormedix Inc. | Taurolidine treatment for myc-expressing tumors in mammalian bodies |
| WO2020234829A1 (en) | 2019-05-22 | 2020-11-26 | Geistlich Pharma Ag | Methods and compositions for inhibiting gapdh |
| WO2020234833A1 (en) | 2019-05-22 | 2020-11-26 | Geistlich Pharma Ag | Method for treating, preventing, inhibiting or reducing cytokine release |
| CN111671758A (zh) * | 2020-07-06 | 2020-09-18 | 长春迈灵生物工程有限公司 | 牛磺罗定在制备抗hiv病毒药物中的应用 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5210083A (en) | 1986-07-17 | 1993-05-11 | Ed. Geistlich Sohne A.G. Fur Chemische Industrie | Pharmaceutical compositions |
| IE66933B1 (en) * | 1990-01-15 | 1996-02-07 | Elan Corp Plc | Controlled absorption naproxen formulation for once-daily administration |
| US20030027818A1 (en) * | 2001-04-03 | 2003-02-06 | Redmond H. Paul | Treatment of cancers |
| US5972933A (en) * | 1998-01-08 | 1999-10-26 | Ed. Geistlich Sohne Ag Fur Chemische Industrie | Method of treating microbial infections |
| US6555534B1 (en) * | 1998-09-11 | 2003-04-29 | Medpointe Healthcare Inc. | Method and compositions for the control or eradication of Helicobacter pylori |
| US6251896B1 (en) * | 1999-03-24 | 2001-06-26 | Carter-Wallace, Inc. | Compositions and methods for the management of Crohn's disease |
| MXPA02001857A (es) * | 1999-08-24 | 2003-07-14 | Cellgate Inc | Composiciones y metodos para incrementar la entrega de drogas a traves y dentro de tejidos epiteliales. |
| EP1246617B1 (en) * | 1999-12-06 | 2006-09-13 | Rhode Island Hospital | Use of taurolidine or taurultam for the manufacture of a medicament for the treatment of ovarian cancer |
| US20020004502A1 (en) * | 2000-01-05 | 2002-01-10 | Redmond H. Paul | Treatment of inflammatory bowel disease |
| US20040170617A1 (en) * | 2000-06-05 | 2004-09-02 | Finegold Sydney M. | Method of treating diseases associated with abnormal gastrointestinal flora |
| AU779362B2 (en) * | 2000-10-27 | 2005-01-20 | Ed. Geistlich Soehne Ag Fuer Chemische Industrie | Treatment of tumor metastases and cancer |
| DE50113344D1 (de) * | 2001-01-31 | 2008-01-17 | Evonik Roehm Gmbh | Multipartikuläre arzneiform, enthaltend mindestens zwei unterschiedlich überzogene pelletformen |
| US20030092707A1 (en) * | 2001-10-19 | 2003-05-15 | Redmond H. Paul | Treatment of breast cancer |
| JP5041664B2 (ja) * | 2002-06-21 | 2012-10-03 | ロレアル | 脱毛症を治療するためのタウリンの利用 |
| US20060198886A1 (en) * | 2005-03-01 | 2006-09-07 | Jenkins Richard B | Medicament having coated methenamine combined with acidifier |
| CA2626016A1 (en) * | 2005-10-21 | 2007-06-21 | Panacea Biotec Limited | Pharmaceutical composition comprising at least one anticancer drug and at least one polymer |
| DK1882476T3 (da) * | 2006-07-25 | 2009-03-09 | Claus Herdeis | Fremstilling af antimikrobielle formuleringer under anvendelse af 7-oxa-2-thia1,5-diazabicyklo(3.3.1)nonan-2,2-dion |
-
2011
- 2011-06-01 CA CA2801309A patent/CA2801309C/en active Active
- 2011-06-01 AU AU2011262308A patent/AU2011262308B2/en active Active
- 2011-06-01 JP JP2013513002A patent/JP5926243B2/ja active Active
- 2011-06-01 BR BR112012030641A patent/BR112012030641B8/pt not_active IP Right Cessation
- 2011-06-01 ES ES11758551.3T patent/ES2614878T3/es active Active
- 2011-06-01 WO PCT/IB2011/001539 patent/WO2011151722A2/en not_active Ceased
- 2011-06-01 US US13/701,372 patent/US9028866B2/en active Active
- 2011-06-01 CN CN201180036488.8A patent/CN103118669B/zh active Active
- 2011-06-01 EP EP11758551.3A patent/EP2575783B1/en active Active
-
2016
- 2016-02-29 JP JP2016037487A patent/JP2016155826A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| AU2011262308B2 (en) | 2014-07-31 |
| CN103118669B (zh) | 2016-01-13 |
| US20130089606A1 (en) | 2013-04-11 |
| BR112012030641B8 (pt) | 2022-06-14 |
| CN103118669A (zh) | 2013-05-22 |
| WO2011151722A3 (en) | 2012-05-24 |
| BR112012030641B1 (pt) | 2022-05-24 |
| JP2016155826A (ja) | 2016-09-01 |
| CA2801309C (en) | 2018-07-17 |
| US9028866B2 (en) | 2015-05-12 |
| HK1183228A1 (zh) | 2013-12-20 |
| CA2801309A1 (en) | 2011-12-08 |
| JP2013527224A (ja) | 2013-06-27 |
| BR112012030641A2 (pt) | 2016-08-16 |
| EP2575783B1 (en) | 2017-01-11 |
| WO2011151722A2 (en) | 2011-12-08 |
| AU2011262308A1 (en) | 2013-01-10 |
| JP5926243B2 (ja) | 2016-05-25 |
| EP2575783A2 (en) | 2013-04-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2614878T3 (es) | Métodos y composiciones para terapia farmacéutica oral | |
| RU2606593C1 (ru) | Покрытая кишечнорастворимой оболочкой композиция масла мяты перечной с контролируемым высвобождением, состоящая из множества частиц, и связанные с ней способы | |
| ES2189232T5 (es) | Microgránulos de omeprazol protegidos gástricamente, procedimiento de obtención y preparaciones farmacéuticas | |
| KR20210134313A (ko) | 심리적, 인지적, 행동적 및/또는 기분 장애의 치료를 위한 5ht 수용체 아고니스트를 포함하는 조성물 및 방법 | |
| CL2022000033A1 (es) | Composición farmacéutica para suministro nasal | |
| BRPI0711606A2 (pt) | formulações de hidrocloreto de duloxetina de liberação retardada | |
| KR20100014629A (ko) | 타크로리무스의 변형제형 | |
| ME02946B (me) | Dimer buprenorfina i njegova upotreba u lecenju gastrointestinalnih poremecaja | |
| JP2008280351A5 (enExample) | ||
| CN104940169B (zh) | 一种右兰索拉唑缓释胶囊及其制备方法 | |
| ITTO20070356A1 (it) | "composizione per il rilascio di principi attivi da dispositivi di impianto" | |
| RU2621128C2 (ru) | Фармацевтическая композиция для пролонгированного высвобождения триметазидина | |
| KR102023559B1 (ko) | 제어형 하이드로코티손 방출 제형 | |
| US20160324913A1 (en) | Enteric Coated Multiparticulate Controlled Release Peppermint Oil Composition and Related Methods | |
| ES2261006B1 (es) | Pellet multicapa de liberacion controlada de metilfenidato. | |
| ES2373164T3 (es) | Composición farmacéutica de liberación controlada de clorhidrato de venlafaxina, y procedimiento para la preparación de la misma. | |
| Lee et al. | Modulating drug release from gastric-floating microcapsules through spray-coating layers | |
| KR20090016612A (ko) | 피페리디노알칸올 및 충혈완화제의 복합제를 포함하는 약학조성물 | |
| JP6294457B2 (ja) | 低減した送達変動性のための複数の投薬要素を備えるメサラミン医薬組成物 | |
| JP2020073583A (ja) | ミューオピオイド受容体アンタゴニストとオピオイド剤との組み合わせ剤形 | |
| US20130251804A1 (en) | Method to improve the safety of handling of high potency drugs in solid dosage forms without changing their efficacy | |
| US20110020439A1 (en) | Delayed release compositions of duloxetine | |
| JP2016504390A5 (enExample) | ||
| ES2307043T3 (es) | Forma de administracion para aplicacion oral para substancias activas acidas y anfoteras dificilmente solubles. | |
| ES2377473B1 (es) | Pellets entéricos de duloxetina. |